[Clinical trial of UFT against disseminated breast cancer].
A study was carried out in 32 patients with disseminated breast cancer to determine the clinical responses and side-effects of daily administration of 400-600 mg of UFT. According to the Japan Mammary Cancer Society's criteria of response, more than partial response was observed in 11 out of 32 cases (34.4%). Side-effects were observed in 15 cases (46.9%) and these mainly consisted of those involving slight myelosuppression and upper digestive organs, such us nausea and anorexia.